novottf-200t + docetaxel + immune checkpoint inhibitors

This is a **combination therapy** consisting of the delivery of Tumor Treating Fields (TTFields) using the medical device **NovoTTF-200T**, combined with the chemotherapeutic agent **docetaxel** and **immune checkpoint inhibitors**. - **NovoTTF-200T** is a portable device that delivers low intensity, wave-like electric fields (TTFields) to tumor locations, disrupting cancer cell division and inducing cell death. TTFields specifically target rapidly dividing cancer cells by interfering with charged cellular elements involved in mitosis. The device has regulatory designations for use with other systemic agents in non-small cell lung cancer (NSCLC) and liver cancer, but is under clinical investigation when used in combination with docetaxel and immune checkpoint inhibitors in metastatic NSCLC[3][4][5]. - **Docetaxel** is a microtubule inhibitor that disrupts mitotic spindle formation, leading to cell cycle arrest and apoptosis. - **Immune checkpoint inhibitors** (ICI) are biologics that block inhibitory signals in T cells, mainly targeting proteins such as PD-1, PD-L1, or CTLA-4, enhancing anti-tumor immune responses. This regimen is used in clinical trials for **advanced/metastatic non-small cell lung cancer** to evaluate potential improvements in survival and treatment response when TTFields are added to standard therapies[3][4].

Other names

Tumor Treating Fields device + docetaxel + immune checkpoint inhibitorsTTFields + docetaxel + immune checkpoint inhibitors